Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06685887 | A Clinical Study Evaluating the Efficacy of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal Metastasis | PHASE2 | RECRUITING | 34 | — | — | Feb 15, 2025 | Dec 1, 2027 | Apr 11, 2025 | 1 | China |
The proportion of patients who achieved R0 resection
| Arm | Type | Description |
|---|---|---|
| HIPEC combined with SOX and Tislelizumab | EXPERIMENTAL | The participants volunteering to take HIPEC combined with SOX and immune checkpoint inhibitors will be assigned to this group. |
| Name | Type | Description |
|---|---|---|
| HIPEC | DRUG | HIPEC treatment (Oxaliplatin, physiological saline at 43°C for 60 min) was performed after the Laparoscopic exploratory surgery. |
| SOX | DRUG | Oxaliplatin, 130 mg, i.v. + S-1 (40 mg per dose for BSA \<1.25; 60 mg per dose for BSA 1.25 to 1.5; 60 mg per dose for BSA ≥1.5, twice daily for each treatment cycle d1-14, q3w |
| Immune Checkpoint Inhibitors | DRUG | Tislelizumab, 200 mg, q3w |
Inclusion Criteria: 1. 18-75 years 2. Men, or non-pregnant and non-lactating women 3. Pathological diagnosis as gastric malignant tumor 4. diagnosis of peritoneal metastasis \[peritoneal cancer index (PCI) ≤ 12 points\] by laparoscopic exploration 5. Normal major organ function: 1\) HB ≥ 90 g/L； A...